FDA approves Cobenfy, a new treatment for schizophrenia
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.
Bharti Rana Jayshankar – Founder
She brings in more than 30 years of experience in content building, architecture, writing, editing and storytelling. Ms Jayshankar has worked in the Economic Times daily, IBT Times, Investopedia and more than a dozen content firms as a content strategist and planner.
Jay Shankar – Co-founder
He has almost three decades of experience in journalism. He has worked with national dailies such as ET, Indian Express, The Pioneer, The Hindu, Agence France Presse and Bloomberg.
HQ Team 27 September, 2024: The U.S. Food and Drug Administration (FDA) has approved Cobenfy (xanomeline and trospium chloride) for the treatment of schizophrenia in.
HQ Team September 27, 2024: World leaders convened at the United Nations General Assembly (UNGA) on September 26, to address the escalating threat.
HQ Team September 27, 2024: The Central Drugs Standard Control Organisation (CDSCO) of India recently issued a notification regarding identifying 52 spurious drugs.
Evotec SE has signed a technology pact with Novo Nordisk to produce cell therapy products for clinical development and commercial use, according to.
Pfizer Inc.’s sickle cell therapy involving Oxbryta has been voluntarily withdrawn from global markets due to painful complications and death, according to a.
Merck & Co., announced its trial drug along with a combination of the company’s Keytruda therapy failed to meet the main goal of.
Amgen Inc.’s experimental drug to treat patients suffering from a rare muscle-weakening disease, myasthenia gravis, has shown positive results in an end-stage trial.
IntraBio Inc, a biotechnology company focused on rare and neurogenerative diseases, got the US regulator’s nod for a drug to treat a certain.
September 24, 2024: Teva Pharmaceuticals presented new research demonstrating effective strategies for switching adult patients with schizophrenia from Perseris to Uzedy (risperidone extended-release.
The US national public agency has issued a Health Alert Network on the ongoing outbreak of the Clade I monkeypox virus, warning its.